Effect Of Semaglutide In Coronary Atheroma Plaque

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05071417

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (from the registry)
Registry
  • NCT NCT05071417
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05071417. Allocation not applicable; no masking; primary purpose treatment. Start 2021-11 (anticipated); primary completion 2024-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect Of Semaglutide In Coronary Atheroma Plaque
Acronym
SEPLA
Condition
Atheroscleroses, Coronary
Intervention (Drug)
Semaglutide
Lead sponsor
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (class: other)

Record details

Record id
cardio:ct-nct05071417
Content hash
6e7e32540677e24131445da601f0c587c6a72b993e29896eb249fe3ee099dfe3